相关实验视频
Updated: Jun 24, 2025

14:57
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
9.5K
内源性p53抑制剂TIRR将全身代谢健康与瘤性活性分离
Eva Tsaousidou1, Jędrzej Chrzanowski2, Pascal Drané3
1Sabri Ülker Center for Metabolic Research, Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Cell reports
|June 11, 2024
概括
删除Tudor相互作用修复调节器 (TIRR) 激活瘤抑制器p53,减少癌症,但导致肥胖和胰岛素抵抗等代谢问题. 这突显了癌症保护和代谢健康之间的权衡.
科学领域:
- 在瘤学瘤学.
- 代谢健康 代谢健康
- 分子生物学分子生物学
背景情况:
- 代谢健康和瘤发生之间的关系尚未完全理解.
- 图多相互作用修复调节器 (TIRR) 被确定为p53结合蛋白1 (53BP1) 中介的p53激活的抑制剂.
- 研究TIRR的作用提供了关于瘤抑制和代谢调节的见解.
研究的目的:
- 通过调节TIRR来增强瘤抑制活性的生理后果.
- 确定TIRR删除对癌症发展和体内和人体组织中的代谢健康的影响.
- 阐明TIRR瘤保护和代谢作用对p53的依赖性.
主要方法:
- 利用小鼠TIRR的遗传删除来研究其对p53激活,癌症保护和代谢参数的影响.
- 评估了标准饮食中的TIRR缺乏小鼠的代谢健康状况,包括体重和胰岛素抵抗.
- 在人类脂肪组织样本中,与BMI和胰岛素抵抗相关的TIRR表达.
- 采用特定组织的模型来研究脂肪组织和中枢神经系统 (CNS) 在调节葡萄糖平衡和氧生成中的作用.
主要成果:
- 除TIRR可以选择性地激活p53,从而对抗癌症有显著的保护作用.
- 缺乏TIRR的小鼠表现出全身代谢失衡,其特点是超重和胰岛素抵抗.
- 人体脂肪组织中TIRR表达的减少与增加的BMI和胰岛素抵抗有关.
- 失去TIRR可以改善p53异合体 (p53HET) 小鼠的存活率,并且与p53HET癌症患者的无进展存活率相对应.
- 在TIRR缺乏的小鼠中,TIRR的瘤保护和代谢作用都取决于p53,因为它们在p53缺失时被废除.
- 脂肪组织和中枢神经系统主要对TIRR表达作出反应,分别调节葡萄糖恒温和氧化生成.
结论:
- TIRR删除代表了一种新的范式,将代谢放松调节与减少瘤发生联系起来.
- 调节TIRR为癌症提供了潜在的治疗策略,但必须仔细考虑其对代谢健康的影响.
- 这些发现强调了瘤抑制途径和全身代谢调节之间的复杂相互作用.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K

